Author:
Leung Daniel,Mu Xiaofeng,Duque Jaime S. Rosa,Cheng Samuel M. S.,Wang Manni,Zhang Wenyue,Zhang Yanmei,Tam Issan Y. S.,Lee Toby S. S.,Lam Jennifer H. Y.,Chan Sau Man,Cheang Cheuk Hei,Chung Yuet,Wong Howard H. W.,Lee Amos M. T.,Li Wing Yan,Chaothai Sara,Tsang Leo C. H.,Chua Gilbert T.,Cheong Kai-Ning,Au Elaine Y. L.,Kwok Janette S. Y.,Chan Koon Wing,Chong Patrick C. Y.,Lee Pamela P. W.,Ho Marco H. K.,Lee Tsz Leung,Tu Wenwei,Peiris Malik,Lau Yu Lung
Abstract
Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.
Subject
Immunology,Immunology and Allergy